Characteristics of the patients
human papillomavirus-16
PATHOLOGY, CERVICAL INTRAEPITHELIAL NEOPLASIA
From June 15, 2019, to December 30, 2021, a total of 283 patients were enrolled at 4 centers; 165 eligible patients were randomly assigned to the high-dose (n = 43), intermediate-dose (n = 40), and low-dose (n = 41) groups, and 40 patients were assigned to the placebo group for the full analysis set (Patients’ enrollment and random assignment. Screening exclusions at registration included women who were human papillomavirus-16 negative and those not diagnosed with cervical intraepithelial neoplasia 2 or 3 by central pathology (*). The remaining 165 patients were enrolled and participated in a double-blind random assignment. A total of 165 patients were assigned to all groups, and 3 patients were discontinued from the study.